This brand name is authorized in Austria, Croatia, Cyprus, Estonia, France, Lithuania, Netherlands, Poland, Spain.
The drug VIZITRAV contains one active pharmaceutical ingredient (API):
1
|
UNII
WJ68R08KX9 - TRAVOPROST
|
|
Travoprost, a prostaglandin F2α analogue, is a highly selective full agonist which has a high affinity for the prostaglandin FP receptor, and reduces the intraocular pressure by increasing the outflow of aqueous humour via trabecular meshwork and uveoscleral pathways. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| S01EE04 | Travoprost | S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EE Prostaglandin analogues |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| EE | Ravimiamet | 1799433, 1799444 |
| ES | Centro de información online de medicamentos de la AEMPS | 81831 |
| FR | Base de données publique des médicaments | 67138300 |
| HR | Agencija za lijekove i medicinske proizvode | HR-H-128588342 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1090702, 1090703 |
| NL | Z-Index G-Standaard, PRK | 61093 |
| PL | Rejestru Produktów Leczniczych | 100335068 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.